{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:32:51Z","timestamp":1794058371511,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160710"],"award-info":[{"award-number":["RP160710"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Computational models have been successful in predicting drug sensitivity in cancer cell line data, creating an opportunity to guide precision medicine. However, translating these models to tumors remains challenging. We propose a new transfer learning workflow that transfers drug sensitivity predicting models from large-scale cancer cell lines to both tumors and patient derived xenografts based on molecular pathways derived from genomic features. We further compute feature importance to identify pathways most important to drug response prediction. We obtained good performance on tumors (AUROC\u2009=\u20090.77) and patient derived xenografts from triple negative breast cancers (RMSE\u2009=\u20090.11). Using feature importance, we highlight the association between ER-Golgi trafficking pathway in everolimus sensitivity within breast cancer patients and the role of class II histone deacetylases and interlukine-12 in response to drugs for triple-negative breast cancer. Pathway information support transfer of drug response prediction models from cell lines to tumors and can provide biological interpretation underlying the predictions, serving as a steppingstone towards usage in clinical setting.<\/jats:p>","DOI":"10.1038\/s41598-022-20646-1","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T17:05:45Z","timestamp":1664298345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Molecular pathways enhance drug response prediction using transfer learning from cell lines to tumors and patient-derived xenografts"],"prefix":"10.1038","volume":"12","author":[{"given":"Yi-Ching","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid T.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"20646_CR1","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","volume":"74","author":"JL Wilding","year":"2014","unstructured":"Wilding, J. L. & Bodmer, W. F. Cancer cell lines for drug discovery and development. Cancer Res. 74, 2377\u20132384 (2014).","journal-title":"Cancer Res."},{"key":"20646_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"20646_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/nbt1239","volume":"24","author":"MAQC Consortium","year":"2006","unstructured":"MAQC Consortium. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151\u20131161 (2006).","journal-title":"Nat. Biotechnol."},{"key":"20646_CR4","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/gb-2014-15-3-r47","volume":"15","author":"P Geeleher","year":"2014","unstructured":"Geeleher, P., Cox, N. J. & Huang, R. S. Clinical drug response can be predicted using baseline gene expression levels and in vitrodrug sensitivity in cell lines. Genome Biol. 15, R47 (2014).","journal-title":"Genome Biol."},{"key":"20646_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/cancers13040885","volume":"13","author":"RF Gruener","year":"2021","unstructured":"Gruener, R. F. et al. Facilitating drug discovery in breast cancer by virtually screening patients using in vitro drug response modeling. Cancers 13, 885 (2021).","journal-title":"Cancers"},{"key":"20646_CR6","doi-asserted-by":"publisher","first-page":"1840014","DOI":"10.1142\/S0219720018400140","volume":"16","author":"T Turki","year":"2018","unstructured":"Turki, T., Wei, Z. & Wang, J. T. L. A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction. J. Bioinform. Comput. Biol. 16, 1840014 (2018).","journal-title":"J. Bioinform. Comput. Biol."},{"key":"20646_CR7","doi-asserted-by":"crossref","unstructured":"Cheng, L. et al. Computational cancer cell models to guide precision breast cancer medicine. Genes 11, (2020).","DOI":"10.3390\/genes11030263"},{"key":"20646_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"20646_CR9","first-page":"820","volume":"18","author":"F Azuaje","year":"2017","unstructured":"Azuaje, F. Computational models for predicting drug responses in cancer research. Brief. Bioinform. 18, 820\u2013829 (2017).","journal-title":"Brief. Bioinform."},{"key":"20646_CR10","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41598-021-82612-7","volume":"11","author":"Y-C Tang","year":"2021","unstructured":"Tang, Y.-C. & Gottlieb, A. Explainable drug sensitivity prediction through cancer pathway enrichment. Sci. Rep. 11, 3128 (2021).","journal-title":"Sci. Rep."},{"key":"20646_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/jamia\/ocaa212","volume":"28","author":"Y Kim","year":"2021","unstructured":"Kim, Y. et al. Anticancer drug synergy prediction in understudied tissues using transfer learning. J. Am. Med. Inform. Assoc. 28, 42\u201351 (2021).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"20646_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12859-018-2465-y","volume":"19","author":"SR Dhruba","year":"2018","unstructured":"Dhruba, S. R., Rahman, R., Matlock, K., Ghosh, S. & Pal, R. Application of transfer learning for cancer drug sensitivity prediction. BMC Bioinf. 19, 497 (2018).","journal-title":"BMC Bioinf."},{"key":"20646_CR13","doi-asserted-by":"publisher","first-page":"i501","DOI":"10.1093\/bioinformatics\/btz318","volume":"35","author":"H Sharifi-Noghabi","year":"2019","unstructured":"Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C. & Ester, M. MOLI: Multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics 35, i501\u2013i509 (2019).","journal-title":"Bioinformatics"},{"key":"20646_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/nar\/gkn653","volume":"37","author":"CF Schaefer","year":"2009","unstructured":"Schaefer, C. F. et al. PID: The pathway interaction database. Nucleic Acids Res. 37, 674\u2013679 (2009).","journal-title":"Nucleic Acids Res."},{"key":"20646_CR15","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498\u2013D503 (2020).","journal-title":"Nucleic Acids Res."},{"key":"20646_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00709-019-01462-3","volume":"257","author":"M Mughees","year":"2020","unstructured":"Mughees, M., Chugh, H. & Wajid, S. Vesicular trafficking\u2013related proteins as the potential therapeutic target for breast cancer. Protoplasma 257, 345\u2013352 (2020).","journal-title":"Protoplasma"},{"key":"20646_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s11658-021-00262-z","volume":"26","author":"A Koscielny","year":"2021","unstructured":"Koscielny, A. et al. mTOR controls endoplasmic reticulum\u2013Golgi apparatus trafficking of VSVg in specific cell types. Cell. Mol. Biol. Lett. 26, 18 (2021).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"20646_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12703\/r\/10-50","volume":"10","author":"C Makhoul","year":"2021","unstructured":"Makhoul, C. & Gleeson, P. A. Regulation of mTORC1 activity by the Golgi apparatus. Fac. Rev. 10, 50 (2021).","journal-title":"Fac. Rev."},{"key":"20646_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jir.2014.0026","volume":"35","author":"M Esquivel-Vel\u00e1zquez","year":"2015","unstructured":"Esquivel-Vel\u00e1zquez, M. et al. The role of cytokines in breast cancer development and progression. J. Interferon Cytokine Res. 35, 1\u201316 (2015).","journal-title":"J. Interferon Cytokine Res."},{"key":"20646_CR20","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.7150\/thno.45219","volume":"10","author":"J Jin","year":"2020","unstructured":"Jin, J. & Zhao, Q. Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. Theranostics 10, 6231\u20136244 (2020).","journal-title":"Theranostics"},{"key":"20646_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12586","volume":"40","author":"A Kumar","year":"2018","unstructured":"Kumar, A. et al. Leishmania infection activates host mTOR for its survival by M2 macrophage polarization. Parasite Immunol. 40, e12586 (2018).","journal-title":"Parasite Immunol."},{"key":"20646_CR22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00432-018-2646-0","volume":"144","author":"S Garvin","year":"2018","unstructured":"Garvin, S., Oda, H., Arnesson, L.-G., Lindstr\u00f6m, A. & Shabo, I. Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery. J. Cancer Res. Clin. Oncol. 144, 1253\u20131263 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"20646_CR23","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.7150\/jca.47566","volume":"12","author":"J Ye","year":"2021","unstructured":"Ye, J. et al. Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer. J. Cancer 12, 2886\u20132892 (2021).","journal-title":"J. Cancer"},{"key":"20646_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.20517\/2394-4722.2017.60","volume":"4","author":"CA Neumann","year":"2018","unstructured":"Neumann, C. A., Levine, K. & Oesterreich, S. Targeting adenosine receptor 2B in triple negative breast cancer. J. Cancer Metastasis Treat. 4, 13 (2018).","journal-title":"J. Cancer Metastasis Treat."},{"key":"20646_CR25","doi-asserted-by":"crossref","unstructured":"Hamidullah, Changkija, B. & Konwar, R. Role of interleukin-10 in breast cancer. Breast Cancer Res. Treat. 133, 11\u201321 (2012).","DOI":"10.1007\/s10549-011-1855-x"},{"key":"20646_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/onc.2009.334","volume":"29","author":"A Villagra","year":"2010","unstructured":"Villagra, A., Sotomayor, E. M. & Seto, E. Histone deacetylases and the immunological network: Implications in cancer and inflammation. Oncogene 29, 157\u2013173 (2010).","journal-title":"Oncogene"},{"key":"20646_CR27","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/690901","volume":"2012","author":"PV Licciardi","year":"2012","unstructured":"Licciardi, P. V. & Karagiannis, T. C. Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol. 2012, 690901 (2012).","journal-title":"ISRN Hematol."},{"key":"20646_CR28","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1158\/1541-7786.MCR-08-0299","volume":"6","author":"V Duong","year":"2008","unstructured":"Duong, V. et al. Specific activity of class II histone deacetylases in human breast cancer cells. Mol. Cancer Res. 6, 1908\u20131919 (2008).","journal-title":"Mol. Cancer Res."},{"key":"20646_CR29","doi-asserted-by":"publisher","first-page":"114156","DOI":"10.18632\/oncotarget.23169","volume":"8","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio, M. et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget 8, 114156\u2013114172 (2017).","journal-title":"Oncotarget"},{"key":"20646_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cancers13020167","volume":"13","author":"B Mirlekar","year":"2021","unstructured":"Mirlekar, B. & Pylayeva-Gupta, Y. IL-12 family cytokines in cancer and immunotherapy. Cancers 13, 167 (2021).","journal-title":"Cancers"},{"key":"20646_CR31","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1158\/1078-0432.CCR-20-3944","volume":"27","author":"ML Telli","year":"2021","unstructured":"Telli, M. L. et al. Intratumoral plasmid IL12 expands CD8+T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti\u2013PD-1 therapy. Clin. Cancer Res. 27, 2481\u20132493 (2021).","journal-title":"Clin. Cancer Res."},{"key":"20646_CR32","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1038\/s41467-021-25393-x","volume":"12","author":"KC Hicks","year":"2021","unstructured":"Hicks, K. C. et al. Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. Nat. Commun. 12, 5151 (2021).","journal-title":"Nat. Commun."},{"key":"20646_CR33","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1158\/1078-0432.CCR-19-3034","volume":"26","author":"M Sinn","year":"2020","unstructured":"Sinn, M. et al. TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: Next-generation sequencing results from the CONKO-001 Trial. Clin. Cancer Res Off. J. Am. Assoc. Cancer Res. 26, 3732\u20133739 (2020).","journal-title":"Clin. Cancer Res Off. J. Am. Assoc. Cancer Res."},{"key":"20646_CR34","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0735","author":"Y-C Tang","year":"2022","unstructured":"Tang, Y.-C. & Gottlieb, A. SynPathy: Predicting drug synergy through drug-associated pathways using deep learning. Mol. Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0735 (2022).","journal-title":"Mol. Cancer Res."},{"key":"20646_CR35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, 955\u2013961 (2012).","journal-title":"Nucleic Acids Res."},{"key":"20646_CR36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318\u20131325 (2015).","journal-title":"Nat. Med."},{"key":"20646_CR37","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/bioinformatics\/btw344","volume":"32","author":"Z Ding","year":"2016","unstructured":"Ding, Z., Zu, S. & Gu, J. Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics 32, 2891\u20132895 (2016).","journal-title":"Bioinformatics"},{"key":"20646_CR38","doi-asserted-by":"publisher","first-page":"17899","DOI":"10.1038\/s41598-020-74882-4","volume":"10","author":"RT Powell","year":"2020","unstructured":"Powell, R. T. et al. Pharmacologic profiling of patient-derived xenograft models of primary treatment-na\u00efve triple-negative breast cancer. Sci. Rep. 10, 17899 (2020).","journal-title":"Sci. Rep."},{"key":"20646_CR39","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","volume":"184","author":"JS Lee","year":"2021","unstructured":"Lee, J. S. et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell 184, 2487-2502.e13 (2021).","journal-title":"Cell"},{"key":"20646_CR40","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"20646_CR41","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"20646_CR42","first-page":"118","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostat. Oxf. Engl. 8, 118\u2013127 (2007).","journal-title":"Biostat. Oxf. Engl."},{"key":"20646_CR43","doi-asserted-by":"crossref","unstructured":"Liu, L. & Ruan, J. Network-based pathway enrichment analysis. In 2013 IEEE International Conference on Bioinformatics and Biomedicine 218\u2013221 (2013).","DOI":"10.1109\/BIBM.2013.6732493"},{"key":"20646_CR44","doi-asserted-by":"crossref","unstructured":"Szklarczyk, D. et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, (2019).","DOI":"10.1093\/nar\/gky1131"},{"key":"20646_CR45","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/1535-7163.MCT-19-0273","volume":"18","author":"R Roy","year":"2019","unstructured":"Roy, R., Winteringham, L. N., Lassmann, T. & Forrest, A. R. R. Expression levels of therapeutic targets as indicators of sensitivity to targeted therapeutics. Mol. Cancer Ther. 18, 2480\u20132489 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"20646_CR46","doi-asserted-by":"crossref","unstructured":"Shapley, L. S. 17. A value for n-person games. 307\u2013318 (1953).","DOI":"10.1515\/9781400881970-018"},{"key":"20646_CR47","unstructured":"Lundberg, S. M. & Lee, S.-I. A unified approach to interpreting model predictions. In NIPS\u201917 Proceedings of the 31st International Conference on Neural Information Processing Systems 4768\u20134777 (2017)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20646-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T17:12:13Z","timestamp":1664298733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20646-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20646"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20646-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16109"}}